Fosamax and Osteonecrosis of the Jaw: A Clinical Evidence Review
Latest update (2026-05)
FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]
From General Health Information to Targeted Risk Assessment
The legacy of general health and science information has long provided a foundation for public understanding of medical conditions and treatment options. Within this broad context, discussions of bone health and osteoporosis management have historically emphasized the benefits of bisphosphonate therapies, such as Fosamax, in reducing fracture risk. This established framework has served as a baseline for patient education and clinical guidance, focusing on therapeutic efficacy and routine monitoring. As this heritage evolves, a more nuanced perspective emerges when considering specific adverse outcomes linked to prolonged medication exposure. The transition from general health awareness to occupational exposure concern becomes relevant when examining the relationship between Fosamax use and the development of osteonecrosis of the jaw. This pivot requires shifting focus from broad population-level health information to a targeted clinical evidence review that assesses causation in individual cases. The bridge concept here involves recognizing that while general health contexts address medication benefits, a deeper inquiry into risk factors—including duration of therapy and patient-specific vulnerabilities—is necessary. This transition does not assert mechanistic claims but rather reframes the discussion to prioritize evidence-based evaluation of exposure and outcome, moving from a general informational stance to a focused clinical scrutiny of potential harm.
Clinical Evidence Linking Fosamax to Osteonecrosis of the Jaw
Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its clinical utility in reducing fracture risk is well established, but its use has been associated with a serious adverse effect: osteonecrosis of the jaw (ONJ). Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region. Clinical presentation typically involves areas of exposed bone that persist for more than eight weeks, often accompanied by pain, swelling, infection, or drainage. Diagnosis is primarily clinical, based on visual inspection and history, and may be supported by imaging studies to assess the extent of bone involvement. The condition can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal or other pre-existing dental disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).
Mechanistic Pathways and Risk Factors
Fosamax pharmacology involves inhibition of osteoclast-mediated bone resorption, which reduces bone turnover. While this mechanism is beneficial for increasing bone mass in osteoporosis, it may also impair the normal remodeling and repair processes in the jawbone. Multiscale characterization of jawbone tissue has provided comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). The mechanistic pathways linking Fosamax to ONJ are thought to involve suppression of bone turnover, leading to microdamage accumulation and reduced ability to repair minor injuries, such as those from dental procedures. Additionally, bisphosphonates may have anti-angiogenic effects, further compromising blood supply to the jawbone. The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw under Warnings and Precautions. This section states that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). It also notes that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the label does not provide specific guidance on the optimal duration of bisphosphonate therapy for fracture prevention, noting that the optimal duration of use has not been determined and that for low-risk patients, drug discontinuation after 3 to 5 years may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This lack of definitive duration guidance may leave some patients exposed to prolonged therapy without clear risk-benefit assessment for ONJ.
Causation Considerations and Clinical Implications
Causation-related considerations for affected patients involve evaluating the temporal relationship between Fosamax exposure and the development of ONJ. The time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, and a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This pattern supports a causal association, as the condition improves with drug cessation and recurs upon re-exposure. However, in placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), indicating that ONJ is a rare event that may not be captured in typical trial populations. The timeline between exposure and documented harm can vary widely, from days to months after starting the drug, and may be influenced by the presence of risk factors such as dental procedures or infection. For patients who develop ONJ while on Fosamax, the label advises discontinuation if severe symptoms develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Management typically involves conservative measures such as oral rinses, antibiotics, and avoidance of further dental surgery. The risk of ONJ may be reduced by performing a dental examination and completing any necessary invasive dental procedures before initiating bisphosphonate therapy, and by maintaining good oral hygiene during treatment. In summary, the clinical evidence supports a causal link between Fosamax use and osteonecrosis of the jaw, with mechanistic plausibility, temporal association, and dechallenge-rechallenge patterns. The prescribing information includes warnings about this risk, but the optimal duration of therapy remains undefined, which may contribute to prolonged exposure and increased risk. Patients and clinicians should weigh the benefits of fracture reduction against the rare but serious risk of ONJ, particularly in those with additional risk factors.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is osteonecrosis of the jaw (ONJ) and how is it diagnosed?
Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region. Clinical presentation typically involves areas of exposed bone that persist for more than eight weeks, often accompanied by pain, swelling, infection, or drainage. Diagnosis is primarily clinical, based on visual inspection and history, and may be supported by imaging studies to assess the extent of bone involvement (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).
What are the known risk factors for developing ONJ while taking Fosamax?
Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal or other pre-existing dental disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).
Is there a causal link between Fosamax and ONJ?
Yes, clinical evidence supports a causal link. The time to onset of symptoms varied from one day to several months after starting the drug. Most patients had relief of symptoms after stopping the drug, and a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This pattern supports a causal association.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Free Case & Eligibility Review
Individuals with documented Fosamax exposure and a related diagnosis may request an independent, no-cost eligibility review.